ClinicalTrials.gov
public full text
Public Domain
Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia
The objective of this study is to compare the modulation of pergolide, a D1/D2 receptor agonist, to placebo in non-acute schizophrenic subjects under concomitant therapy with atypical antipsychotics on specific PFC functions. Further aims are to assess the influence of pergolide on psychopathology and extrapyramidal symptoms in comparison to placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase 2 Trial of a Nicotinic Agonist in Schizophrenia#1309259
- Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder#1140028
- A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients#827155
- Nicotinic Receptors and Schizophrenia#1138040
- Dopamine D3 Receptor Occupancy in Bipolar Depression#813357
Record · ID 1453987
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive